Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
3.25
Dollar change
-0.26
Percentage change
-7.41
%
IndexRUT P/E- EPS (ttm)-2.16 Insider Own15.37% Shs Outstand48.85M Perf Week7.97%
Market Cap158.85M Forward P/E- EPS next Y-2.62 Insider Trans0.00% Shs Float41.36M Perf Month-22.62%
Income-104.16M PEG- EPS next Q-0.64 Inst Own87.25% Short Float8.69% Perf Quarter-23.71%
Sales0.00M P/S- EPS this Y-40.16% Inst Trans-6.65% Short Ratio1.72 Perf Half Y-70.51%
Book/sh3.57 P/B0.91 EPS next Y-13.13% ROA-55.16% Short Interest3.60M Perf Year-79.21%
Cash/sh3.74 P/C0.87 EPS next 5Y- ROE-62.16% 52W Range1.76 - 26.35 Perf YTD-85.68%
Dividend Est.- P/FCF- EPS past 5Y-26.63% ROI-57.38% 52W High-87.67% Beta2.38
Dividend TTM- Quick Ratio8.11 Sales past 5Y0.00% Gross Margin- 52W Low84.66% ATR (14)0.59
Dividend Ex-Date- Current Ratio8.11 EPS Y/Y TTM-25.02% Oper. Margin- RSI (14)47.54 Volatility23.13% 17.91%
Employees103 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price22.10
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-65.49% Payout- Rel Volume1.90 Prev Close3.51
Sales Surprise- EPS Surprise-3.99% Sales Q/Q- EarningsNov 14 BMO Avg Volume2.10M Price3.25
SMA20-1.34% SMA50-15.86% SMA200-64.90% Trades Volume3,972,109 Change-7.41%
Date Action Analyst Rating Change Price Target Change
Oct-10-24Initiated UBS Buy $10
Feb-05-24Initiated Jefferies Buy $36
Nov-29-23Initiated William Blair Outperform $38
Oct-24-23Initiated Cantor Fitzgerald Overweight $40
Oct-19-23Initiated Stifel Buy $31
Sep-05-23Initiated Citigroup Buy $22
Jul-18-23Initiated Guggenheim Buy $34
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $3 → $16
Aug-30-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $3
Dec-08-21Initiated Wells Fargo Overweight $17
Nov-26-24 08:00AM
Nov-18-24 07:00AM
Nov-14-24 07:00AM
Nov-06-24 08:00AM
Oct-17-24 03:06PM
04:30PM Loading…
Sep-25-24 04:30PM
Aug-28-24 08:00AM
Aug-21-24 04:32AM
Aug-08-24 07:00AM
Jul-08-24 07:01PM
12:30PM
Jul-02-24 08:00AM
Jun-14-24 02:00AM
May-29-24 08:00AM
May-16-24 05:23PM
11:54AM Loading…
May-15-24 11:54AM
07:00AM
May-13-24 08:00AM
Mar-23-24 05:31AM
Mar-21-24 01:53PM
07:00AM
Mar-20-24 07:00AM
Mar-08-24 08:50AM
Feb-27-24 10:11AM
08:00AM
Feb-01-24 04:30PM
Jan-31-24 08:00AM
Jan-08-24 07:00AM
Jan-02-24 08:00AM
Dec-18-23 08:49PM
04:30PM Loading…
Nov-28-23 04:30PM
Nov-09-23 08:10AM
07:00AM
Nov-06-23 08:15AM
07:00AM
Oct-30-23 08:00AM
Oct-09-23 09:40AM
Oct-02-23 09:14AM
07:00AM
Oct-01-23 11:00AM
Sep-25-23 08:50AM
Sep-19-23 08:00AM
Sep-01-23 02:00PM
11:30AM
Aug-31-23 09:55AM
08:30AM
Aug-30-23 08:00AM
Aug-25-23 10:13AM
Aug-23-23 08:50AM
Aug-22-23 08:00AM
Aug-15-23 01:46PM
Aug-10-23 07:00AM
Aug-01-23 10:00AM
Jul-24-23 08:00AM
Jul-18-23 02:58PM
Jun-20-23 08:00AM
Jun-08-23 11:14AM
May-31-23 08:00AM
May-24-23 07:33AM
May-22-23 04:30PM
May-17-23 10:16PM
04:01PM
May-16-23 07:00AM
May-11-23 08:39AM
07:00AM
May-02-23 04:35PM
May-01-23 07:00AM
Apr-25-23 01:07PM
08:00AM
Apr-13-23 04:30PM
Mar-31-23 07:00AM
Mar-16-23 07:00AM
Mar-14-23 07:14AM
Feb-28-23 08:00AM
Feb-19-23 10:53AM
Feb-17-23 06:43PM
Feb-06-23 12:00PM
Jan-31-23 09:40AM
Jan-09-23 07:00AM
Jan-05-23 08:00AM
Jan-03-23 05:40AM
Dec-30-22 09:03AM
Dec-23-22 09:40AM
Dec-13-22 11:41AM
Dec-12-22 01:37PM
Dec-08-22 07:00AM
Dec-07-22 09:55AM
Nov-22-22 08:00AM
Nov-16-22 11:26AM
Nov-10-22 07:00AM
Oct-11-22 10:06AM
07:00AM
Oct-06-22 08:00AM
Oct-05-22 06:26AM
Sep-26-22 08:00AM
Sep-10-22 07:00AM
Sep-06-22 08:00AM
Aug-29-22 01:58PM
Aug-11-22 07:00AM
Jun-09-22 12:00PM
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder GwendolynSee RemarksJan 19 '24Option Exercise1.0111,00011,11031,000Jan 19 06:30 PM
Binder GwendolynSee RemarksJan 19 '24Sale19.5911,000215,43920,000Jan 19 06:30 PM
Binder GwendolynSee RemarksDec 19 '23Option Exercise1.0111,00011,11031,000Dec 19 08:37 PM
Binder GwendolynSee RemarksDec 19 '23Sale21.8911,000240,78920,000Dec 19 08:37 PM